Abstract:Blocking of costimulatory signals for T cell activation leads to tolerance in several transplantation models, but the underlying mechanisms are incompletely understood. We analyzed the involvement of regulatory T cells (Treg) and deletion of alloreactive cells in the induction and maintenance of tolerance after costimulation blockade in a mouse model of graft-vs-host reaction. Injection of splenocytes from the C57BL/6 parent strain into a sublethally irradiated F1 offspring (C57BL/6 × C3H) induced a GVHR chara… Show more
“…Our data indeed also show a role for Tregs in the effects of costimulation blockade. It has already been suggested by several groups that Tregs are involved in tolerance induction by costimulation blockade (10,(13)(14)(15). CD40L blockade especially was found to be associated with an enhanced Treg function in previous studies (13-15, 19, 20).…”
Section: Discussionmentioning
confidence: 86%
“…We and others have shown that combined blockade of the CD40/ CD40L interaction and the CD28/B7 interaction completely prevents GVHD after allogeneic splenocyte transfer in mice and results in tolerance (8)(9)(10). Separate blockade of these costimulatory pathways is not effective.…”
Section: Mr1 Treatment Prevents Gvhd Induced By Cd4mentioning
confidence: 99%
“…Our previous study documented an expansion of donor Tregs when GVHD mice were treated with MR1 and CTLA-4Ig (10). Other studies have documented that the effect of MR1 is at least partially dependent on Treg activity (13-15, 19, 20), whereas data on the effect of CTLA4Ig on Tregs are controversial (10,13,(21)(22)(23). First, we analyzed the effect of MR1 and different doses of CTLA-4Ig treatment on the numbers of Foxp3 + Tregs.…”
“…Combined treatment with CTLA-4Ig and anti-CD40L mAb is clearly superior over single-agent treatment in mice and in nonhuman primates (8,9). In this context, we have previously demonstrated that treatment with CTLA-4Ig and MR1 (a blocking anti-CD40L mAb) completely prevents GVHD in a fully MHCmismatch "parent into F1" splenocyte transfer mouse model (10). Long-term survival, tolerance, and mixed chimerism were induced only if both reagents were applied together.…”
mentioning
confidence: 99%
“…It is believed that TCR triggering without a costimulatory signal results in T cell hyporesponsiveness (11), followed by peripheral clonal deletion by apoptosis (10,12). It has further been suggested that regulatory T cells (Tregs) are involved (13)(14)(15).…”
Blocking of costimulatory CD28/B7 and CD40/CD40L interactions is an experimental approach to immune suppression and tolerance induction. We previously reported that administration of a combination of CTLA-4Ig and MR1 (anti-CD40L mAb) for blockade of these interactions induces tolerance in a fully mismatched allogeneic splenocyte transfer model in mice. We now used this model to study whether regulatory T cells (Tregs) contribute to immune suppression and why both pathways have to be blocked simultaneously. Mice were injected with allogeneic splenocytes, CD4+ T cells, or CD8+ T cells and treated with MR1 mAb and different doses of CTLA-4Ig. The graft-versus-host reaction of CD4+ T cells, but not of CD8+ T cells, was inhibited by MR1. CTLA-4Ig was needed to cover CD8+ T cells but had only a weak effect on CD4+ T cells. Consequently, only the combination provided full protection when splenocytes were transferred. Importantly, MR1 and low-dose CTLA-4Ig treatment resulted in a relative increase in Tregs, and immune suppressive efficacy was abolished in the absence of Tregs. High-dose CTLA-4Ig treatment, in contrast, prevented Treg expansion and activity, and in combination with MR1 completely inhibited CD4+ and CD8+ T cell activation in a Treg-independent manner. In conclusion, MR1 and CTLA-4Ig act synergistically as they target different T cell populations. The contribution of Tregs to immune suppression by costimulation blockade depends on the concentration of CTLA-4Ig and thus on the degree of available CD28 costimulation.
“…Our data indeed also show a role for Tregs in the effects of costimulation blockade. It has already been suggested by several groups that Tregs are involved in tolerance induction by costimulation blockade (10,(13)(14)(15). CD40L blockade especially was found to be associated with an enhanced Treg function in previous studies (13-15, 19, 20).…”
Section: Discussionmentioning
confidence: 86%
“…We and others have shown that combined blockade of the CD40/ CD40L interaction and the CD28/B7 interaction completely prevents GVHD after allogeneic splenocyte transfer in mice and results in tolerance (8)(9)(10). Separate blockade of these costimulatory pathways is not effective.…”
Section: Mr1 Treatment Prevents Gvhd Induced By Cd4mentioning
confidence: 99%
“…Our previous study documented an expansion of donor Tregs when GVHD mice were treated with MR1 and CTLA-4Ig (10). Other studies have documented that the effect of MR1 is at least partially dependent on Treg activity (13-15, 19, 20), whereas data on the effect of CTLA4Ig on Tregs are controversial (10,13,(21)(22)(23). First, we analyzed the effect of MR1 and different doses of CTLA-4Ig treatment on the numbers of Foxp3 + Tregs.…”
“…Combined treatment with CTLA-4Ig and anti-CD40L mAb is clearly superior over single-agent treatment in mice and in nonhuman primates (8,9). In this context, we have previously demonstrated that treatment with CTLA-4Ig and MR1 (a blocking anti-CD40L mAb) completely prevents GVHD in a fully MHCmismatch "parent into F1" splenocyte transfer mouse model (10). Long-term survival, tolerance, and mixed chimerism were induced only if both reagents were applied together.…”
mentioning
confidence: 99%
“…It is believed that TCR triggering without a costimulatory signal results in T cell hyporesponsiveness (11), followed by peripheral clonal deletion by apoptosis (10,12). It has further been suggested that regulatory T cells (Tregs) are involved (13)(14)(15).…”
Blocking of costimulatory CD28/B7 and CD40/CD40L interactions is an experimental approach to immune suppression and tolerance induction. We previously reported that administration of a combination of CTLA-4Ig and MR1 (anti-CD40L mAb) for blockade of these interactions induces tolerance in a fully mismatched allogeneic splenocyte transfer model in mice. We now used this model to study whether regulatory T cells (Tregs) contribute to immune suppression and why both pathways have to be blocked simultaneously. Mice were injected with allogeneic splenocytes, CD4+ T cells, or CD8+ T cells and treated with MR1 mAb and different doses of CTLA-4Ig. The graft-versus-host reaction of CD4+ T cells, but not of CD8+ T cells, was inhibited by MR1. CTLA-4Ig was needed to cover CD8+ T cells but had only a weak effect on CD4+ T cells. Consequently, only the combination provided full protection when splenocytes were transferred. Importantly, MR1 and low-dose CTLA-4Ig treatment resulted in a relative increase in Tregs, and immune suppressive efficacy was abolished in the absence of Tregs. High-dose CTLA-4Ig treatment, in contrast, prevented Treg expansion and activity, and in combination with MR1 completely inhibited CD4+ and CD8+ T cell activation in a Treg-independent manner. In conclusion, MR1 and CTLA-4Ig act synergistically as they target different T cell populations. The contribution of Tregs to immune suppression by costimulation blockade depends on the concentration of CTLA-4Ig and thus on the degree of available CD28 costimulation.
Heart diseases such as myocardial infarction cause massive loss of cardiomyocytes, but the human heart lacks the innate ability to regenerate. In the adult mammalian heart, a resident progenitor cell population, termed epicardial progenitors, has been identified and reported to stay quiescent under uninjured conditions; however, myocardial infarction induces their proliferation and de novo differentiation into cardiac cells. It is conceivable to develop novel therapeutic approaches for myocardial repair by targeting such expandable sources of cardiac progenitors, thereby giving rise to new muscle and vasculatures. Human pluripotent stem cells such as embryonic stem cells and induced pluripotent stem cells can self-renew and differentiate into the three major cell types of the heart, namely cardiomyocytes, smooth muscle, and endothelial cells. In this review, we describe our current knowledge of the therapeutic potential and challenges associated with the use of pluripotent stem cell and progenitor biology in cell therapy. An emphasis is placed on the contribution of paracrine factors in the growth of myocardium and neovascularization as well as the role of immunogenicity in cell survival and engraftment.
Costimulatory signals are required for priming and activation of naive T cells, while it is less clear how they contribute to induction of regulatory T (Treg)-cell activity. We previously reported that the blockade of the B7-CD28 and CD40L-CD40 interaction efficiently suppresses allogeneic T-cell activation in vivo. This was characterized by an initial rise in Foxp3
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.